{"id":15952,"date":"2023-07-21T23:54:00","date_gmt":"2023-07-21T15:54:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15952"},"modified":"2025-03-03T15:30:00","modified_gmt":"2025-03-03T07:30:00","slug":"biotherus-inc-and-biontech-se-enter-global-license-agreement-for-cancer-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15952","title":{"rendered":"Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies"},"content":{"rendered":"\n

China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license agreement with Germany’s BioNTech SE (NASDAQ: BNTX<\/a>). The deal grants BioNTech exclusive worldwide options to a preclinical-stage bispecific antibody and a clinical-stage monoclonal antibody for cancer therapy. Additionally, Biotheus will provide BioNTech with exclusive licenses to existing panels of VHH binders against multiple targets, with options to generate new panels of VHH binders against targets nominated by BioNTech.<\/p>\n\n\n\n

Financial Terms and Potential Milestones<\/strong>
In exchange for the rights, BioNTech will provide Biotheus with an upfront payment. Following the exercise of options on Biotheus’ preclinical-stage bispecific antibody, Biotheus will also be eligible for clinical, regulatory, and commercial milestone payments, as well as tiered single-digit royalties.<\/p>\n\n\n\n

Biotherus Inc.’s Commitment to Oncology and Inflammatory Diseases<\/strong>
Founded in 2018, Biotheus Inc. is a clinical-stage biotech company dedicated to the discovery, development, and delivery of novel antibodies and cell therapies to address unmet medical needs of patients with oncology and inflammatory diseases worldwide. The company’s product pipeline consists of over 20 Category 1 biologic drugs, showcasing its commitment to innovation in the field.<\/p>\n\n\n\n

BioNTech’s Partnerships with Chinese Companies Post-COVID-19<\/strong>
BioNTech has expanded its partnerships with several China-based companies as it looks to bolster its post-COVID-19 pipeline. The German company granted Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196<\/a>) Greater China rights to its COVID-19 vaccine Comirnaty during the pandemic and has since struck in-licensing deals with Duality Biologics (Suzhou) Co., Ltd and Zhejiang Doer Biologics Co., Ltd in April and July this year, respectively.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[342,774,16,2508,232,3795,159,28,1124,892],"class_list":["post-15952","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biontech","tag-biotheus","tag-cancer","tag-doer-biologics","tag-duality-biologics","tag-duality-biotherapeutics","tag-fosun-pharmaceutical","tag-multi-specific-antibodies","tag-nasdaq-bntx","tag-sha-600196"],"yoast_head":"\nBiotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license agreement with Germany's BioNTech SE (NASDAQ: BNTX). The deal grants BioNTech exclusive worldwide options to a preclinical-stage bispecific antibody and a clinical-stage monoclonal antibody for cancer therapy. Additionally, Biotheus will provide BioNTech with exclusive licenses to existing panels of VHH binders against multiple targets, with options to generate new panels of VHH binders against targets nominated by BioNTech.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15952\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15952\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-21T15:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-03T07:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15952#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15952\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies\",\"datePublished\":\"2023-07-21T15:54:00+00:00\",\"dateModified\":\"2025-03-03T07:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15952\"},\"wordCount\":270,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BioNTech\",\"Biotheus\",\"Cancer\",\"Doer Biologics\",\"Duality Biologics\",\"Duality Biotherapeutics\",\"Fosun Pharmaceutical\",\"Multi-specific antibodies\",\"NASDAQ: BNTX\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15952#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15952\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15952\",\"name\":\"Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-21T15:54:00+00:00\",\"dateModified\":\"2025-03-03T07:30:00+00:00\",\"description\":\"China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license agreement with Germany's BioNTech SE (NASDAQ: BNTX). The deal grants BioNTech exclusive worldwide options to a preclinical-stage bispecific antibody and a clinical-stage monoclonal antibody for cancer therapy. Additionally, Biotheus will provide BioNTech with exclusive licenses to existing panels of VHH binders against multiple targets, with options to generate new panels of VHH binders against targets nominated by BioNTech.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15952#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15952\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15952#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies - Insight, China's Pharmaceutical Industry","description":"China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license agreement with Germany's BioNTech SE (NASDAQ: BNTX). The deal grants BioNTech exclusive worldwide options to a preclinical-stage bispecific antibody and a clinical-stage monoclonal antibody for cancer therapy. Additionally, Biotheus will provide BioNTech with exclusive licenses to existing panels of VHH binders against multiple targets, with options to generate new panels of VHH binders against targets nominated by BioNTech.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15952","og_locale":"en_US","og_type":"article","og_title":"Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15952","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-21T15:54:00+00:00","article_modified_time":"2025-03-03T07:30:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15952#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15952"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies","datePublished":"2023-07-21T15:54:00+00:00","dateModified":"2025-03-03T07:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15952"},"wordCount":270,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BioNTech","Biotheus","Cancer","Doer Biologics","Duality Biologics","Duality Biotherapeutics","Fosun Pharmaceutical","Multi-specific antibodies","NASDAQ: BNTX","SHA: 600196"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15952#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15952","url":"https:\/\/flcube.com\/?p=15952","name":"Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-21T15:54:00+00:00","dateModified":"2025-03-03T07:30:00+00:00","description":"China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license agreement with Germany's BioNTech SE (NASDAQ: BNTX). The deal grants BioNTech exclusive worldwide options to a preclinical-stage bispecific antibody and a clinical-stage monoclonal antibody for cancer therapy. Additionally, Biotheus will provide BioNTech with exclusive licenses to existing panels of VHH binders against multiple targets, with options to generate new panels of VHH binders against targets nominated by BioNTech.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15952#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15952"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15952#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15952"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15952\/revisions"}],"predecessor-version":[{"id":16777,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15952\/revisions\/16777"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}